['metastatic renal cell carcinoma']
['crlx101', 'bevacizumab', 'standard of care (investigator choice)']

        Inclusion Criteria:

          -  Must have histologically confirmed renal cell carcinoma of any pathologic subtype.

          -  Must have unresectable metastatic disease, and have tumor(s) present that is (are)
             evaluable by the RECIST, v1.1; may have spinal-associated metastases but must have
             concluded dexamethasone therapy and be evaluated by the Investigator to have stable
             CNS disease.

          -  Must have received 2 or 3 prior lines of conventional molecularly targeted therapy

          -  Must have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less
             with the exception of Grade 2 alopecia) prior to randomization.

          -  ECOG performance status 0 or 1.

          -  Age 18 years and older.

          -  Life expectancy of at least 3 months.

          -  Must have normal organ and marrow function reported within 14 days prior to
             randomization

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Able to comply with study visit schedule and assessments.

        Exclusion Criteria:

          -  Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or
             radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.

          -  Failure to recover to grade 1 or less all prior adverse events.

          -  Any major surgery within 4 weeks of study randomization.

          -  Any prior treatment with topoisomerase I therapy.

          -  Prior treatment with any drugs or therapies that will be administered during the
             course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or
             the conventional molecularly targeted agent intended for use as standard of care
             treatment.

          -  Patients receiving any other current investigational therapeutic agent.

          -  Other active malignancies

          -  Patients with brain metastasis treated or untreated, or other CNS disease

          -  Any clinically significant cardiac disease defined as NYHA class III or IV.

          -  Uncontrolled hypertension

          -  Uncontrolled concurrent illness

          -  History of non-healing wounds or ulcers.

          -  Pregnancy, or inadequate contraception for men or women of childbearing age, or
             lactating / breast-feeding

          -  Patients with known HIV or with solid organ transplant
      